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Breast cancer is the commonest malignancy among
women in most European countries. Given current pat-
terns of occurrence by age, about one in 12 women will
develop the disease before the age of 75 years (lifetime
risk around 8%), and it typically accounts for 20% or more
of all cancers in women [1]. Breast cancer is thus a major
public health problem, but with the exception of oral con-
traceptives and hormonal replacement therapy [2,3], both
of which also have clear benefits, the known major risk
factors are not amenable to primary prevention. Mass
screening of women over age 50 years by mammography
has been shown to reduce mortality [4]; national mammo-
graphic screening programmes were introduced for
women aged 50–64 years in the UK from 1988 [5] and for
women aged 50–70 years in The Netherlands from 1990
[6], and a regional scheme in Denmark was started in 1991
[7]. Opportunistic screening is also widespread in many
European countries. The incidence of breast cancer has
been increasing in many countries [1,8–11], but the avail-
able treatments have improved [12], survival has improved
[13,14] and mortality has begun to decline [15].
Until recently, international comparisons of regional or
national survival estimates within Europe were bedev-
illed by the lack of comparability of data and methods.
Within the past 5 years, however, evidence of interna-
tional differences in survival from breast cancer [16–18]
(and many other cancers) in Europe has begun to emerge
from the EUROCARE (European Cancer Registry-based
study of survival and care of cancer patients) study. (The
author has been a member of the EUROCARE Project
Management Group since 1989, and is a co-author of
various publications emanating from the project.) In this
article, the evidence for these differences in breast cancer
survival among women in Europe is reviewed, and some
of the possible explanations are considered, with particu-
lar reference to the patterns of survival in the UK and the
extent to which they differ from those of other countries
in Europe.
The EUROCARE study now covers 17 European countries
and is the largest international study of cancer survival. It
includes 3.5 million cancer patients who were diagnosed
between 1978 and 1989, and who have been followed up for
at least 5 years, until the end of 1994 [19]. Data supplied in
a standard format by 45 cancer registries covering a total
population of about 100 million have been subjected to
central quality control and analyzed using standard methods
[20]. Relative survival up to 10 years after diagnosis by age,
sex and country has been estimated for each of 45 cancers
in adults aged 15–99 years at diagnosis.
For women diagnosed with breast cancer during the
period 1978–1985, 5-year survival in 12 countries up to the
end of 1990 ranged from 76% in Switzerland to 44% in
Poland (Fig. 1a). In Switzerland and Finland, survival was
significantly higher than the weighted European average
for participating countries, and significantly lower in
England, Scotland, Estonia and Poland [16].
Detailed analyses of more than 119000 women with breast
cancer showed that survival improved in all 12 countries;
the hazard of death fell by about 2.5% a year for each year
of diagnosis between 1978 and 1985 [13]. Women aged
40–49 years at diagnosis had the best prognosis in all coun-
tries, whereas those under 30 years old had lower survival
than those aged 30–39 years. The hazard of death within
the first 6months after diagnosis was more steeply age-
dependent than after the first 6 months, but gains in sur-
vival over time were most marked among age groups for
which survival was initially the lowest (under 40 and over
80 years old). Within the first 6 months after diagnosis, the
risk of death in each age group (particularly the youngest
and oldest women) was 1.5–3 times higher in England andhttp://breast-cancer-research.com/vol1no1/07oct99/editorial/3
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Scotland than the average for other countries. This com-
parison is statistically robust; it was based on more than
8700 deaths within the first 6months in the UK, and more
than 3800 in the other countries. The relative risk of death
for women with breast cancer in the UK fell at more than
6months after diagnosis, but was still higher in all age
groups than the average for other countries. These pat-
terns suggest that later diagnosis or more advanced stage is
likely to explain some of the survival deficit in the UK,
but that less effective treatment might also play a role.
More recent analyses [18] included 145000 women diag-
nosed in 17 countries during the period 1985–1989 who
were followed up for at least 5 years to the end of 1994
(Fig. 1b). The average 5-year survival rate was 73%, but it
ranged from 58–60% in Eastern Europe (Poland, Estonia
and Slovakia) to 77–81% in Northern and Western Europe
(Sweden, Finland, Iceland, Switzerland, France and Italy).
Five-year survival in England, Scotland and Denmark
(67–71%) was lower than the European average. Patterns
of survival by age were again similar in each country, and
in most countries survival improved over time.
The survival rates reported from EUROCARE include all
cancer patients, take account of all causes of death and are
age standardized. In this, they differ from the survival
rates in randomized clinical trials and hospital studies in
several key respects.
First, although randomized trials measure the best achiev-
able survival, population studies measure the average sur-
vival actually achieved. Clinical trials show what survival
rates are possible under ideal conditions, with the latest
diagnostic techniques and treatment regimens for selected
cancer patients in the care of experienced oncologists,
often in specialized hospitals. Trials rarely include more
than a small fraction of patients with a given cancer, and
incorporation of the results into routine clinical practice
can be slow, either because of delay in acceptance or lack
of equipment or resources [21]. Trials often exclude
elderly patients [22], even though opinion varies widely
on how to treat breast cancer, both for elderly women [23]
and for those under 50 years old [24], and older patients
are less likely to be referred for specialist advice [25]. For
all these reasons, cancer survival among patients recruited
in clinical trials is inevitably higher than the average for all
cancer patients. Survival estimates from trials are essential
for assessing new treatments, but long-term data series
from population-based cancer registries are equally indis-
pensable to assess trends in the survival of all cancer
patients [26]. Observational studies are the public health
counterpart of clinical trials. When comparable data from
many countries are compiled and analyzed to common
standards, it becomes possible to make international com-
parisons of cancer survival rates and of trends in survival
over time. Randomized trials and nonrandomized hospital
studies of cancer survival do not address these questions.
Second, although cancer patients have higher death rates
than the general population, they do not all die of cancer.
This ‘background’ mortality among cancer patients varies
with age and sex, but also between countries and over time.
Relative survival rates take account of background mortality.
A relative survival rate (say, 67%) is the ratio of the observed
survival of a group of cancer patients (say, 60%) to the sur-
vival that they would have experienced had they only died
at the same rate as the general population from which they
came, matched for age, sex and geographic region or country
(say, 90%). Thus, a relative survival rate of 100% would
imply that the mortality of the cancer patients was the same
as that of the general population, not that no-one died. It can
be interpreted as the survival of cancer patients after adjust-
ment for other causes of death [27]. Background mortality
varies by as much as twofold across Europe, so relative sur-
vival rates are required for appropriate comparison of cancer
survival between countries. The age distribution of cancer
Figure 1
Age-standardized 5-year relative survival (%) from breast cancer in
Europe. (a) Women diagnosed 1978–1985, followed up to 1990
[16]. (b) Women diagnosed 1985–1989, followed up to 1994 [18].
National data sets are represented by darker bars and regional or
subnational data sets by lighter bars. The vertical line is the weighted
European average relative survival at 5 years.
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patients also varies between countries, however, and
because relative survival varies with age, international cancer
survival comparisons are adjusted to a common age standard.
Trends in relative survival reflect both improvements in
treatment and the extent to which they have become avail-
able to all cancer patients.
Survival from breast cancer (and many other cancers)
varies with socioeconomic status and region of residence,
both within the UK [14,28,29] and elsewhere in Europe
[17]. Geographic and socioeconomic differences in investi-
gation and treatment have been reported for patients with
cancers of the breast [30–32] and variations in investiga-
tion or departure from treatment guidelines have caused
inequity in survival [24,33,34].
The sensible question is no longer whether international,
regional and socioeconomic differences in cancer survival
exist, but why. The explanations are certain to be multi-
ple, but the observed differences are not simply due to
artefact [13,19,35], chance [36,37], or (solely) to the extent
of disease at the time of diagnosis [38,39]. Delay in diag-
nosis is likely to reduce survival [40], however, and the
risk of death among women with breast cancer in the UK
in the first 6 months after diagnosis has been higher than
that in other European countries [13]. International or
regional differences in survival could be at least partly
attributable to cultural differences that influence the stage
at which disease is diagnosed, as well as to the different
ways in which national health care systems are organized.
The clinical stage of disease at diagnosis is a key prognos-
tic factor. Ideally, survival estimates would be adjusted for
case-mix when making comparisons. International com-
parisons of cancer survival trends after adjustment for clin-
ical stage are complex for three main reasons. First, an
explicit and reliable statement of the clinical stage may
not be available in the medical record [30]. Second, not all
cancer registries have systematically recorded clinical
stage at diagnosis over long periods. Third, the clinical
stage recorded at diagnosis depends on the extent of
investigation, which itself varies between centres and
countries, and the diagnostic basis for the recorded clinical
stage must therefore be taken into account [35,41]. Again,
this information is not routinely available, but random
samples of cancer patients are now being studied within
the EUROCARE project to enable appropriate compari-
son of stage-adjusted survival rates between populations.
Clearly, to the extent that lower survival in a given popu-
lation can be shown to depend on the disease being diag-
nosed at a later stage, as for example in women over age 65
years living in deprived areas [39], it becomes possible to
devise a suitable strategy for earlier diagnosis.
Treatment protocols for breast cancer vary widely, and
adherence to guidelines in the UK appears poor
[23,32,42]. The UK boasts fewer oncologists per head of
population than most comparable European countries
[43], and there is some evidence that breast cancer sur-
vival depends on access to a specialist [44]. A recent audit
in the UK showed that 28% of cancer patients waited
longer to receive radiotherapy than the maximum accept-
able delay set out in professional guidelines; this was
attributed to lack of equipment and staff [45]. The gov-
ernment acknowledged inequitable access to optimal
cancer treatment in the National Health Service in 1995
[46]. Cancer survival in Denmark is also lower than that in
the other Nordic countries, at least in part because Danish
cancer patients appear to be diagnosed at a later stage [47].
It has been suggested that international differences in
cancer survival, especially those reported from the EURO-
CARE study between the UK and other European coun-
tries, are more likely to be due to demographic differences
and to the certification of cancer patients outside the UK
as having died of old age, and not cancer [48].
These suggestions are not tenable. The EUROCARE
data include essentially all cancer patients resident in the
participating regions or countries, and they are not subject
to the selection bias of most hospital case series. Differ-
ences in background mortality by age, sex, calendar period
and region or country are taken into account in the
EUROCARE study, and because the relative survival
rates are age-standardized, they also account for differ-
ences in the age distribution of cancer patients between
countries. Complaints about inaccurate certification of the
cause of death for cancer patients in other countries are
not only misplaced (because there is ample evidence of
inaccurate certification in the UK [49–52]), they are actu-
ally beside the point. Inaccurate certification of death
could certainly influence recorded cancer mortality rates,
but relative survival rates simply reflect the proportion of
cancer patients who are still alive at a given time since
diagnosis, compared with the proportion that would be
expected among a corresponding group of the general
population in the region or country in which they live.
They are not affected by the certified cause of death.
Uncertainties about the quality of death certification and
the reliability with which a given death can be attributed
as due to a previously diagnosed cancer actually underpin
the rationale for relative survival rates as the most reliable
measure for comparisons of survival between countries
and over time [53,54].
In fact, the evidence suggests that many of the observed dif-
ferences in breast cancer survival between countries, regions
and population subgroups are systematic, and can be largely
attributed to differences in access to health services, includ-
ing delay in presentation and diagnosis, and to the overall
quality of care [17,18,20]. Thus, for example, elimination of
the socioeconomic gradient in breast cancer survival inEngland and Wales would eliminate each year more than
500 of the breast cancer deaths that now occur within 5years
of diagnosis. It would also halve the deficit in breast cancer
survival between England and Wales and the average for
Europe [14]. It is hard to imagine any set of biases in data
collection or analysis that could account for survival being
lower in England and in Scotland than in most comparable
European countries for breast cancer in women (and for
many other cancers in both sexes), but as high as or higher
than the European average survival for breast cancer in men
(and for Hodgkin’s disease and cancers of the larynx and
testis). It would also be remarkable for any set of biases to
result in such similar dependence of survival with age at
diagnosis in each of 17 countries.
In July 1999, the UK government acknowledged that the
UK lags behind other European countries in cancer survival
[55]: an uncomfortable but salutary recognition of the need
for improvement. Such improvement should be part of a
broad strategy to control cancer. It will require more rapid
referral from primary care to hospital, more rigorous adher-
ence to consensus guidelines, and, perhaps above all, the
availability of resources for enough specialists to deliver the
best available treatment to all breast cancer patients.
Improvements in breast cancer survival for the population
as a whole will also require that diagnosis is made at an
earlier stage of the disease, and this in turn implies better
public awareness of the need for early diagnosis and its
impact on the chances of survival. The language in which
scientific results are presented to the public is likely to
influence public attitudes to cancer survival. The popular
description of differences in breast cancer survival between
regions or socioeconomic groups as a lottery [56] is a case in
point. It is frequently repeated in mass-circulation newspa-
pers, but it is misleading. Lotteries are fair. A lottery ticket
buys the same chance of winning for rich and poor alike,
regardless of residence. This inadequate presentation of
the facts may lead the public to believe that, as in a lottery
– which demands hope before the draw, but fatalism after
it – the differences in survival are simply due to chance,
and that little or nothing can be done to change them.
Earlier diagnosis and prompt, universal access to optimal
treatment should reduce both socioeconomic inequalities
and international differences in survival from breast cancer
among women in Europe.
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